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Summary
Detailed recommendations for the treatment
of testicular cancer exist and due to the stringent
application of the standard therapies, most pa-
tients can nowadays be cured. Moreover in the
treatment of early stage disease, active surveillance
is now a cornerstone of treatment. Hence there is
a clear need for recommendations regarding the
long-term follow-up of these young patients.
These have to be safe, feasible and the intensity of
procedures have to reflect the known risk of recur-
rence.
Different proposals have been published but
they differ widely especially in terms of frequency
and modality of imaging. In the last few years, new
evidence has become available regarding the re-
lapse pattern of different disease stages of testicu-
lar cancer, the use of imaging in follow-up and the
risks of excessive radiation due to imaging, in par-
ticular with CT scans. In this article, an interdisci-
plinary,multinational working group has reviewed
the evidence and based on this has formulated
practical recommendations for the follow-up of
patients with testicular cancer.
Key words: follow-up; malignant germ cell tu-
mour; recommendations; testicular cancer
This article has
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Introduction
Substantial progress has been made in the
treatment of malignant germ cell tumours of the
testis in the last three decades. Until the mid-sev-
enties, radiotherapy was the only curative option
for these patients. Since the introduction of cis-
platin-based chemotherapy, the majority of pa-
tients with metastatic testicular cancer can now be
cured. European recommendations for the diag-
nosis and treatment of germ cell tumours have
been published and recently updated [1, 2].Due to
the stringent application of standard chemother-
apy followed by resection of residual disease, re-
lapse rates and mortality have been reduced even
more within the last 15 years [3].
Moreover, the increased use of “active surveil-
lance” programs for patients with stage I semino-
matous and non-seminomatous germ cell tumours
has changed the landscape. Active surveillance
means that no adjuvant treatment is administered
despite a known risk for recurrence. Instead, the
patient is followed closely and treatment is started
as soon as recurrence is detected.This has become
an accepted approach because the survival rates
between active surveillance and adjuvant therapies
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are comparable. Therefore “active surveillance” is
more than just follow-up, but a strategy to avoid
overtreatment and to use chemotherapy only for
those patients who do really need it. Surveillance-
based options particularly require clear recom-
mendations for follow-up schedules. These have
to be safe, feasible and the frequency of proce-
dures have to reflect the known risk of recurrence.
There is no international consensus regarding
the follow-up of patients with stage I malignant
germ cell tumours or patients in complete remis-
sion after curative treatment. Oncological and
urological organisations/societies in different
countries have published their guidelines: Euro-
pean Association of Urology (EAU) [4], German
Cancer Study Group [5],American NCCN guide-
lines [6] and European ESMO guidelines [7, 8].
These guidelines differ considerably especially in
regard to the frequencies and types of imaging
procedures.
A recent publication has shown that evidence-
based follow-ups could be formulated based on
the knowledge of different recurrence risks and
recurrence patterns [9]. Patients should therefore
be grouped into risk categories.An ideal follow-up
schedule identifies a recurrence early without
causing harm by using unnecessary radiation in
these young long-term survivors.
The excessive risks of the radiation due to sin-
gle or repeated computed tomography (CT) have
been calculated [10, 11]. A single chest CT scan
has about a 1000-times higher radiation dose than
a single posterio-anterior chest X-ray [10]. The
radiation exposure of each CT scan carries a small
carcinogenic risk which is even more important in
the young patient population. For example: a typ-
ical CT examination of the abdomen with an ef-
fective dose of 10 mSv increases the risk of fatal
cancer induction by approximately 1:2000. Re-
peated examinations lead to a cumulative risk: if
for example a patient has a yearly CT scan from
the age of 20 until the age of 75, his risk of devel-
oping a malignancy due to these examinations
may be as high as 4% [11]. While these calcula-
tions are discussed controversially, it is clear that
every effort should be made to minimise the radi-
ation burden.
All of these considerations have to be taken
into account when devising follow-up schedules
for young patients who have a relatively low risk of
recurrence. Risk-adaptation of the guidelines is
certainly of high importance.
Apart from tumour recurrence, follow-ups
should include detection of long-term side effects
of chemotherapy and radiotherapy. Hypogonad-
ism, metabolic syndrome and cardiovascular
disease as well as secondary malignancies are the
most important long-term sequelae [12–16]. Pa-
tients who have undergone chemotherapy as well
as radiotherapy have a particularly excessive risk
for cardiovascular events or secondary tumours
[14].
The following recommendations were ini-
tially developed by an interdisciplinary working
group of Swiss medical oncologists, urologists and
radiation oncologists in 2007 and 2008.They were
presented and discussed by a multinational group
with oncologists from both Germany and Austria
in 2009. They represent the opinion of the in-
volved authors according to the existing evidence
and are based on broad personal experience.How-
ever, they do not represent certified guidelines.
The recommendations should help clinicians
who are treating patients with testicular cancer.
However, they can only cover the most frequent
clinical situations and may have to be adapted to
the specific features in an individual patient. It is
important to recognise that a tertiary centre with
special expertise in the follow-up and treatment of
testicular cancer has to be contacted in selected
cases.
The evidence and recommendations have
been graded according to the guidelines defined
by the American Society of Clinical Oncology.
They are explained in Appendix A and are given in
the text in square brackets.
Classification of follow-up groups
Testicular cancers are generally classified as
seminomatous (seminoma) and non-seminoma-
tous germ cell tumours (non-seminoma) of the
testis. Mixed germ cell tumours belong to the
group of non-seminomas.
The stage of disease and the choice of treat-
ment (active surveillance vs chemotherapy vs radio-
therapy) play a very important role for defining
follow-up schedules. This is most obvious in the
case of stage I disease where the risk of recurrence
differs substantially between patients that have re-
ceived adjuvant treatment or not. Whether che-
motherapy or radiotherapy has been applied, in-
fluences the pattern of recurrence and long-term
toxicity and therefore also has to be taken into
account.
Metastatic testicular cancers are classified ac-
cording to the International Germ Cell Cancer
Collaborative Group (IGCCCG [17]) risk groups.
Allocation according to good, intermediate or
poor prognosis group is highly prognostic with
5-year survival differing from >90%, 75% and
50%, respectively.
In respect to follow-up schedules, we have de-
vised nine groups:
Seminomatous germ cell tumours (Semi-
noma):
– Seminoma stage I
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– Adjuvant chemotherapy with carboplatin
– Adjuvant radiotherapy
– Active surveillance
– Seminoma stage IIA/B, treated with radio-
therapy
– Seminoma stage IIB/C and III: good progno-
sis group with complete remission after che-
motherapy [residual disease <3 cm or residual
disease >3 cm with negative positron emission
tomography-(PET-)CT twomonths after end
of treatment].
For the rare case of seminoma patients with
residual postchemotherapy disease >3 cm and a
positive PET-CT (performed at an adequate
chemotherapy-PET interval of at least two
months) or patients with metastatic seminoma in
the intermediate prognosis group, individual fol-
low-up is recommended, preferably at centres
with special expertise in the field.
Non-seminomatous germ cell tumours
(Non-seminoma):
– Non-seminoma stage I
– Active surveillance, low risk
– Active surveillance, high risk
– Adjuvant chemotherapy
– Non-seminoma stage II–III: good prognosis
group with complete remission after chemo-
therapy (CR after chemotherapy alone or af-
ter resection of residual masses).
Patients with metastatic non-seminomatous
germ cell tumours who have non-resectable resid-
ual disease as well as patients with metastatic non-
seminomatous germ cell tumours in the interme-
diate/poor prognosis group are not included in the
recommendations. These patients require follow-
up on an individual basis by an experienced centre.
Modalities of follow-up
General recommendations
Follow-ups should be performed by a physi-
cian who has profound knowledge and experience
in the treatment and follow-up of patients with
germ cell tumours.
Thorough medical history and examination
including palpation of axillary, supra- and infradi-
aphragmal regional lymphnodes and of the re-
maining testis are the cornerstone of each follow-
up visit. Serum tumour markers, AFP (alpha-feto-
protein), HCG (human chorionic gonadotropin)
and LDH (lactate dehydrogenase), must be
checked at every visit. If possible, the tumour
markers should always be checked in the same
qualified laboratory. The role of LDH in the fol-
low-up is debatable. It has limited sensitivity and
specificity and a high rate of false-positive tests are
found. However, as shown in a recent publication,
it can contribute to identify recurrence in a signif-
icant number of cases [18]. Cautious interpreta-
tion of LDH is certainly necessary.
Evidence for the choice of imaging modality
Undoubtedly, CT scans of the thorax, abdo-
men and pelvis have to be performed for staging
purposes at the time of diagnosis of a testicular
cancer.
There are only few publications, however, that
have focused on the modalities of imaging in the
follow-up of testicular cancers. Two retrospective
studies [19, 20] are noteworthy. White et al.
showed that a CT of the pelvis is generally not
necessary in this setting because recurrence out-
side the abdomen is very rare. There is a group of
patients at increased risk of pelvic recurrence who
must have pelvic CT included: bulky abdominal
disease (>5 cm), previous history of maldescent
testis or orchidopexy, history of previous scrotal
surgery and invasion of the carcinoma into the tu-
nica vaginalis of the testis [19] [Level III, B]. As a
matter of fact, in most departments of radiology
the pelvis is included in the CT of the abdomen
due to the short examination times with new scan-
ners. However, there is clearly more radiation ex-
posure by adding the pelvis. It is therefore gener-
ally recommended only to scan the pelvis if the
above mentioned risk factors are present or if the
patient has received radiotherapy treatment for
seminoma stage I (no “dogleg” radiotherapy).
Another publication [20] raises the question of
whether a CT of the thorax is necessary or if
standard chest X rays are sufficient for follow-up
of patients with stage I non-seminoma. In this
retrospective analysis, tumour recurrence was
diagnosed in all cases by raised tumour markers,
abdominal disease or visible metastases in conven-
tional imaging, suggesting that an additional chest
CT would have been of little additional value [20]
[Level III, B]. Therefore we recommend chest
X rays instead of chest CTs for routine follow-ups
of most testicular cancer patients. In case of chest
X rays, only posterio–anterior imaging is recom-
mended.
Whether ultrasound could replace a CT scan
of the abdomen for the evaluation of the retroperi-
toneum, is under debate. Certainly, abdominal ul-
trasound is highly dependent on the experience of
the examiner and the anatomy and preparation of
the patient. Ultrasound appears to have similar
sensitivity and specificity for detection of retro-
peritoneal metastases in patients with testicular
cancer as compared to a CT of the abdomen [21,
22] [Level III, B]. However, we recommend a CT
scan in all cases where there is need to find a small
retroperitoneal mass because ultrasound of the
retroperitoneum has not been validated in pro-
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spective trials and must be regarded as experimen-
tal for this purpose.Whenever the main aim is to
exclude the presence of a larger retroperitoneal
mass (e.g., growing teratoma), we recommend an
ultrasound of the abdomen, mainly for the pur-
pose of sparing additional radiation risk. If either
the physician is not skilled enough or the patient
is not suitable for ultrasound, a CT scan of the ab-
domen is the better choice.
The use of magnetic resonance imaging
(MRI) of the retroperitoneum is a reasonable al-
ternative imaging modality with no radiation ex-
posure. However, there is no general access to
MRI in all areas and experience with its interpre-
tation is limited at the moment.ThereforeMRI of
the retroperitoneum is currently not generally
recommended, but remains an option for special-
ised centres with MRI resources and experienced
radiologists. Trials evaluating the use of MRI are
running.
Contrary to its use for the evaluation of pure
seminoma postchemotherapy residual lesions,
PET or PET-CT have no role in the follow-up of
malignant germ cell tumours of the testis [23]
[Level III, B].
Ultrasound of the remaining testis
Patients after contralateral testis biopsy with-
out evidence of testicular intraepithelial neoplasia
(TIN, carcinoma in situ) do not need ultrasound
of the testis at follow-up. The same holds true for
patients whose remaining testis has been irradi-
ated due toTIN. Patients <30 years with a low tes-
tis volume (<12 ml) are at a higher risk of develop-
ing a contralateral tumor [1]. Biopsy should be
offered in these cases. Without a biopsy, we rec-
ommend that these patients have an annual ultra-
sound of the testis for 10 years.We further recom-
mend manual clinical examination of the contra-
lateral testis with every follow-up visit and a
consecutive ultrasound in case of any suspicious
findings.
It should be recommended to all patients that
they do self-examination of the remaining testis.
Follow-up for long-term toxicity
Patients who have been cured with chemo-
therapy or radiotherapy may develop late toxicity
[12–16].This includes cardiovascular disease,met-
abolic syndrome (arterial hypertension, impaired
glucose tolerance, hyperlipidemia, obesity) as well
as hypogonadism and secondary malignancies.
Regular check-ups of blood pressure, weight, Body
Mass Index (BMI) as well as blood lipids are rec-
ommended at baseline and annually afterwards.
Patients should be checked for hormonal imbal-
ances (total testosterone, LH, FSH) one year after
diagnosis and then on a yearly basis. In case of
pathological findings or a suggestive history of hy-
pogonadism (e.g., missing morning erection), the
hormonal status should be determined repeatedly
on an individual basis. In case of symptomatic tes-
tosterone deficiency, substitution has to be dis-
cussed.
It is very important that these patients are ad-
vised to adapt their lifestyle to control additional
risk factors (e.g., no smoking, weight control, reg-
ular physical exercise).
The general recommendations for patients
with testicular cancer are included in the respec-
tive follow-up schedules.
Recommendations for follow-up
Seminomatous germ cell tumours (Seminoma)
Stage I seminomas have a recurrence risk of
12–31% depending on tumour size and invasion
of the rete testis. However, both risk factors have
not been evaluated prospectively [24]. Active sur-
veillance or adjuvant treatment with either radio-
therapy or chemotherapy with carboplatin are
equal treatment options according to published
guidelines [1, 2]. For follow-up purposes it is im-
portant to distinguish the different risks of recur-
rence related to each modality. Patients after adju-
vant treatment with radiotherapy or carboplatin
are expected to have a recurrence risk of only
about 5%. Therefore the follow-up schedule can
be adapted accordingly. Martin et al. have calcu-
lated the annual risk of recurrence using more
than 5000 stage I seminoma patients from differ-
ent trials [25] [Level III, B].They could show that,
independent of the treatment modality, the risk of
recurrence is highest in the first two years and de-
creases rapidly afterwards. The risk of recurrence
5 years after adjuvant treatment is <0.3% annually.
In a recently published meta-analysis, Mead et al.
demonstrated that recurrence in 2466 patients af-
ter adjuvant treatment for stage I seminoma very
rarely occurred after more than 3 years (0.2% of
all patients). Moreover, they found that 7 of 11 re-
currences were found by scheduled abdominal
CTs (at 12 and 24 months) after adjuvant carbo-
platin. However, CT scans of the chest and pelvis
can safely be omitted in this patient group as they
did not detect recurrences [26] [Level III, B] (table
1). In contrast, isolated pelvic and mediastinal re-
currence can be found after adjuvant radiotherapy
(paraaortic strip only) and therefore the follow-up
tools and schedule have to be adapted accordingly
(table 2).
There is controversy regarding the question
of how many imaging investigations should be
performed for active surveillance of stage I semi-
noma patients. A trial addressing this very ques-
tion has just been initiated in the UK (TRISST;
[27]). In this 4-arm trial, 3 vs 7 scans and CT vs
MRI are evaluated. Until these results will be
360
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Table 1
Seminoma stage I:
after adjuvant
carboplatin.
Abbreviations: BP = blood pressure, BMI = Body Mass Index, Creat = serum creatinine
1
ultrasound of contralateral testis in patients without biopsy of contralateral testis
available, we propose to perform four CT scans
within the first two years. After that, CT may be
replaced by ultrasound. This is a practical ap-
proach minimising the radiation exposure by
maintaining the imaging frequency with an accept-
able alternative imaging modality (table 3). Fol-
low-up with imaging is discontinued after 5 years.
Regarding stage II seminoma patients, stan-
dard treatment is radiotherapy (stage IIA and B).
Chemotherapy is a valuable alternative for all
stages and is the standard for stage IIC. For stage
II patients after radiotherapy, the follow-up sched-
ule is the same as for stage I patients. In cases
where no “dogleg” radiotherapy has been per-
formed (standard treatment includes “dogleg” ra-
diotherapy), a CT scan of the pelvis has to be in-
cluded (table 4).
Patients after chemotherapy for metastatic
disease in the good prognosis group who have
achieved a complete remission are expected to
have a low recurrence rate (10–18%). After two
years, no more regular CT imaging is recom-
mended (table 5).
In general, we recommend continuing clinical
follow-ups (see general recommendations) for up
to 10 years. In the case of treated patients, specific
long-term toxicity (e.g., gastritis, cardiovascular
disease, secondary malignancies) may occur and
patients’ symptoms and complaints should be
taken seriously.
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Table 2
Seminoma stage I:
after adjuvant
radiotherapy.
Abbreviations: BP = blood pressure, BMI = Body Mass Index, Creat = serum creatinine
1
ultrasound of contralateral testis in patients without biopsy of contralateral testis
362
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Table 3
Seminoma stage I:
active surveillance.
Abbreviations: BP = blood pressure, BMI = Body Mass Index, Creat = serum creatinine
1
ultrasound of contralateral testis in patients without biopsy of contralateral testis
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Table 4
Seminoma stage
IIA and IIB: after
radiotherapy.
Abbreviations: BP = blood pressure, BMI = Body Mass Index, Creat = serum creatinine
1
ultrasound of contralateral testis in patients without biopsy of contralateral testis
364
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Abbreviations: BP = blood pressure, BMI = Body Mass Index, Creat = serum creatinine
1
ultrasound of contralateral testis in patients without biopsy of contralateral testis
2
only if presence of supradiaphragmal disease at presentation
Table 5
Seminoma stage
IIB/C–III: good
prognosis group after
chemotherapy (CR
or residual disease
<3 cm or residual
disease >3 cm but
PET negative).
Stage I non-seminomatous germ cell tumours
are divided into a low-risk group with a recurrence
risk of approximately 15–20% and a high-risk
group with a recurrence risk of 40–50%. The
presence of vascular invasion in the primary testis
tumour has become the most important and
widely accepted risk factor for relapse [28, 29].
Following the risk-adapted treatment strategy, sur-
veillance has been recommended for low-risk (no
vascular invasion) stage I non-seminomas [1, 2],
whereas high-risk (with vascular invasion) patients
have been offered adjuvant chemotherapy with
2 cycles of BEP (bleomycin, etoposide, cisplatin),
which reduces the risk of recurrence from 50% to
approximately 2% [30]. The additional benefit of
adjuvant chemotherapy is a reduced need for fol-
low-up (table 8). Active surveillance is also an op-
tion for high-risk patients who are not willing to
undergo adjuvant chemotherapy [1, 2]. Active sur-
veillance can spare unnecessary chemotherapy for
a significant proportion of patients but careful fol-
low-ups are needed to ensure that recurrence is di-
agnosed while the patient is still in a good progno-
sis group situation, in order to maintain the excel-
Non-seminomatous germ cell tumours (Non-seminoma)
365
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Table 6
Non-seminoma stage I
low risk: active
surveillance.
Abbreviations: BP = blood pressure, BMI = Body Mass Index, Creat = serum creatinine
1
ultrasound of contralateral testis in patients without biopsy of contralateral testis
lent outcome of close to 100% disease-specific
survival for the whole population.
In 20–25% of patients, tumour markers are
negative and imaging is the only possibility to di-
agnose recurrence in these patients. The best evi-
dence regarding the frequency of imaging for ac-
tive surveillance in low-risk stage I non-seminoma
patients comes from a large randomised phase III
trial [31] [Level I, A]. This trial showed that 2 CT
scans within the first year of follow-up (at 3 and 12
months) are equal to 5 CT scans, in terms of de-
tection of recurrence in the low-risk group. For
low-risk patients, the frequency of CT scans can
therefore be safely reduced accordingly (table 6).
However, the same tight follow-up schedule for
clinical visits and tumour markers as in the trial
should also be pursued in daily clinical practice.
For high-risk patients, this trial does not provide
enough evidence. Therefore we recommend a to-
tal of six imaging procedures during the first two
years in this patient group (table 7).
Patients with metastatic non-seminoma in the
good prognosis group who achieve complete re-
mission with chemotherapy only or by additional
complete resection of residual disease have recur-
rence rates that are below 10% [32]. Follow-up
procedures, including imaging, can therefore be
largely reduced especially in cases where a retro-
peritoneal lymph node dissection (RPLND) has
been performed. For patients without RPLND,
two additional CT scans of the abdomen are rec-
ommended. When RPLNDwas performed in pa-
366
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Table 7
Non-seminoma
stage I high risk:
active surveillance.
Abbreviations: BP = blood pressure, BMI = Body Mass Index, Creat = serum creatinine
1
ultrasound of contralateral testis in patients without biopsy of contralateral testis
tients with complete resolution of retroperitoneal
lymph nodes, it was demonstrated that mature ter-
atoma or even viable tumours can be found in
10–20% of these cases [33, 34]. Therefore we rec-
ommend annual ultrasound of the retroperito-
neum to rule out growing teratoma in these pa-
tients (table 9).
Again in all cases, we generally recommend to
continue clinical follow-up (see general recom-
mendations) for up to 10 years.
Conclusions
These recommendations are meant to serve as
guidance and to help making decisions in the fol-
low-up of testicular cancer patients. Most clinical
situations are covered here. Recommendations,
however, cannot address individual questions and
needs. Therefore it is very important and in the
patients’ best interest to discuss special cases in a
multidisciplinary team of an experienced centre.
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Table 8
Non-seminoma stage I
high risk: after
adjuvant chemother-
apy.
Abbreviations: BP = blood pressure, BMI = Body Mass Index, Creat = serum creatinine
1
ultrasound of contralateral testis in patients without biopsy of contralateral testis
This is even more important as, due to the lack of
data, some of the recommendations are not based
on published evidence.
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Abbreviations: BP = blood pressure, BMI = Body Mass Index, Creat = serum creatinine
1
ultrasound of contralateral testis in patients without biopsy of contralateral testis
2
only if presence of supradiaphragmal disease at presentation
3
if patient has not undergone retroperitoneal resection
Table 9
Non-seminoma stage
II–III good prognosis
group: CR after
chemotherapy alone
or CR after chemo-
therapy followed by
resection of residual
masses.
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Appendix A
Levels of evidence and grading
of recommendation
Level Type of Evidence
I Evidence is obtained from meta-analysis
of multiple, well-designed, controlled
studies or from randomised trials with
low false-positive and low false-negative
errors (high power).
II Evidence is obtained from at least one
well-designed experimental study or from
randomised trials with high false-positive
and/or negative errors (low power).
III Evidence is obtained from well-designed
quasi-experimental studies such as non-
randomised, controlled single-group,
pre-post, cohort, time or matched case-
control series.
IV Evidence is from well-designed, non-ex-
perimental studies such as comparative
and correlational descriptive and case
studies.
V Evidence is from case reports and clinical
examples.
Grade Grading of recommendation
A There is evidence of type I or consistent
findings from multiple studies of types II,
III or IV.
B There is evidence of types II, III or IV
and findings are generally consistent.
C There is evidence of types II, III and IV
but findings are inconsistent.
D There is little or no systematic empirical
evidence.
